Learn what PROTACs (proteolysis-targeting chimeras) are, how they work via the ubiquitin–proteasome system, and why protein degraders can outperform traditional small molecule inhibitors in oncology and beyond.
Learn how targeted protein degraders, especially PROTACs, are transforming small molecule drug discovery by degrading disease‑driving proteins, expanding druggable targets beyond classical enzyme and receptor inhibition.
Learn how PROTACs (Proteolysis-Targeting Chimeras) work, why they can target “undruggable” cancer proteins, and how small molecule degraders like ARV-110 and ARV-471 are changing oncology treatment.